What the company does
Aribiolab develops vaccines and immunotherapies designed to trigger stronger immune responses against infectious diseases, chronic conditions such as hepatitis B, and cancer.
Its core technology is a proprietary adjuvant platform, adjuvants are substances added to vaccines to amplify the body's immune reaction, built around two formulations, L-pampo® and Lipo-pam®. The company's pipeline centres on a therapeutic hepatitis B vaccine, an improved shingles vaccine, an elderly-focused influenza vaccine, a norovirus vaccine, and cancer vaccines. It is listed on KOSDAQ, South Korea's technology and small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$213.1K
- FY2024US$268.6K
- FY2025US$114.9K
Operating profit
- FY2023−US$4.7M
- FY2024−US$5.6M
- FY2025−US$10.3M
Net income
- FY2023−US$1.3M
- FY2024−US$7.3M
- FY2025−US$11.6M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The filing states that the controlling shareholder became ㈜차바이오텍, placing Aribiolab within the Cha Hospital/Cha Bio Group.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?